Munich - Delayed Quote • EUR
Iovance Biotherapeutics Inc (2LB.MU)
At close: April 26 at 8:03 AM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,189.00
1,189.00
--
--
--
Cost of Revenue
10,755.00
10,755.00
--
--
--
Gross Profit
-9,566.00
-9,566.00
--
--
--
Operating Expense
450,993.00
450,993.00
398,878.00
342,703.00
261,937.00
Operating Income
-460,559.00
-460,559.00
-398,878.00
-342,703.00
-261,937.00
Net Non Operating Interest Income Expense
13,043.00
13,043.00
2,985.00
451.00
2,356.00
Pretax Income
-447,516.00
-447,516.00
-395,893.00
-342,252.00
-259,581.00
Tax Provision
-3,479.00
-3,479.00
--
--
--
Net Income Common Stockholders
-444,037.00
-444,037.00
-395,893.00
-342,252.00
-259,581.00
Diluted NI Available to Com Stockholders
-444,037.00
-444,037.00
-395,893.00
-342,252.00
-259,581.00
Basic EPS
-2.08
-1.89
-2.49
-2.23
-1.88
Diluted EPS
-2.08
-1.89
-2.49
-2.23
-1.88
Basic Average Shares
212,292.25
235,131.00
159,259.00
153,406.00
138,301.00
Diluted Average Shares
212,292.25
235,131.00
159,259.00
153,406.00
138,301.00
Total Operating Income as Reported
-460,559.00
-460,559.00
-398,878.00
-342,703.00
-261,937.00
Total Expenses
461,748.00
461,748.00
398,878.00
342,703.00
261,937.00
Net Income from Continuing & Discontinued Operation
-444,037.00
-444,037.00
-395,893.00
-342,252.00
-259,581.00
Normalized Income
-444,037.00
-444,037.00
-395,893.00
-342,252.00
-259,581.00
Interest Income
13,043.00
13,043.00
2,985.00
451.00
2,356.00
Net Interest Income
13,043.00
13,043.00
2,985.00
451.00
2,356.00
EBIT
-460,559.00
-460,559.00
-398,878.00
-342,703.00
-261,937.00
EBITDA
-427,432.00
-427,432.00
-377,743.00
-328,723.00
-253,225.00
Reconciled Cost of Revenue
10,755.00
10,755.00
--
--
--
Reconciled Depreciation
33,127.00
33,127.00
21,135.00
13,980.00
8,712.00
Net Income from Continuing Operation Net Minority Interest
-444,037.00
-444,037.00
-395,893.00
-342,252.00
-259,581.00
Normalized EBITDA
-427,432.00
-427,432.00
-377,743.00
-328,723.00
-253,225.00
Tax Rate for Calcs
0.00
0.00
--
--
--
12/31/2020 - 11/17/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade